OZ439 clears the first clinical development hurdle | MMV

Published in the British Journal of Clinical Pharmacology, the results of the first trial of OZ439 in healthy human volunteers demonstrate it to be well tolerated in doses up to 1600 mg. The concentration of drug achieved in the blood with these doses should be sufficient to kill malaria parasites for up to 96 hours – considerably longer than that of currently available artemisinin-based antimalarials. These data therefore support the potential of OZ439 as a one-dose cure.

via OZ439 clears the first clinical development hurdle | MMV.

Advertisements


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s